RegCell develops cell therapies designed to restore immune tolerance in autoimmune diseases. Its research focuses on regulatory T cells, known as Tregs, which help control immune responses and prevent the immune system from attacking healthy tissue. The company develops a therapeutic platform based on antigen-specific tolerance and epigenetic reprogramming of Tregs for potential treatment of autoimmune conditions. Its work addresses diseases such as Type 1 Diabetes, Rheumatoid Arthritis, Multiple Sclerosis, Lupus, Crohn’s Disease, and Ulcerative Colitis, with development activities spanning cell therapy research, manufacturing, and clinical translation.